The trademark FARON was filed by Faron Pharmaceuticals Oy, a corporation established under the laws of the Republic of Finland (the "Applicant"). The application was published for oppositions on February 4, 2018, and received one opposition filed on May 2, 2018 by Fagron B.V. on Likelihood of confusion. the opponent was represented by NLO SHIELDMARK B.V. and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued May 2, 2018
The application was filed in Finnish, and Finnish was also language of all opposition proceedings (English was selected as the second language).
Appointment and Replacement of representative of the trademark registration was recorded on October 7, 2018.
The Opposition with reference B 003051377 was partially refused EUTMA/IR according to Article 8(1)(b) EUTMR with decision issued on April 13, 2020 by the EUIPO.
Goods And Services
The mark was filed in class 42 with following description of goods:
Pharmaceutical research and development
Development of pharmaceutical preparations and medicines
Clinical trials
Medical research
All the aforementioned services relating to pharmaceutical preparations for treatment and prevention of ischemic conditions, inflammations and organ damages resulting from tissue traumas, reperfusion injuries, cancer, cancer metastasis, inflammatory conditions and allergic conditions, or to pharmaceutical preparations for treatment and prevention of multiorgan failure, acute lung injury and acute respiratory distress syndrome in adults, adolescents, children, infants and neonates, or to medical and veterinary preparations to prevent inflammations and cancer growth and spread, or to pharmaceutical preparations for the treatment of cancer, or to tumor suppressing agents, or to antineoplastics, or to anti-cancer preparations, or to compounds for treating cancer, or to antibodies for medical use to treat inflammation and cancer growth and spread, or to adjuvants for medical purposes, or to vaccine adjuvants.